Synovial sarcoma
Drug research and approvals for synovial sarcoma: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 21, 2026, 26 studies of synovial sarcoma are recruiting on ClinicalTrials.gov, Health Canada has authorized 3 drug trials for it since 2013, and FDA has 2 approved and 0 open orphan designations naming it.
- Recruiting worldwide: 26
- Trials authorized in Canada: 3
- FDA orphan approvals: 2
- EU medicines: 0
- TLN-499 in Combination With Venetoclax in Patients With Relapsed/Refractory Solid TumorsNCT07713732 · Phase 1 · Treeline Biosciences, Inc. · starts Aug 5, 2026
- A Study to Test the Safety, Tolerability and Effect of ZI-MA4-1 for Patients With Locally Advanced or Metastatic Solid…NCT07613723 · Phase 1 · Zelluna Immunotherapy AS · starts May 11, 2026
- Precision Medicine Approaches for Neoadjuvant Therapy in High-risk Sarcoma PatientsNCT07432932 · Not reported · Royal Marsden NHS Foundation Trust · starts Nov 19, 2021
- N-803 in Patients With Progressive Synovial Sarcoma and Myxoid/Round Cell Liposarcoma Previously Treated With Adoptive…NCT07261657 · Early Phase 1 · Seth Pollack · starts Apr 13, 2026
- Multi-center Study of TBI-1301 (INN: Mipetresgene Autoleucel; Mip-cel) in Patients With NY-ESO-1 Positive Synovial…NCT07174427 · Phase 3 · Takara Bio Inc. · starts Jan 5, 2026
- Dose-escalated, Hypofractionated, Definitive Proton Radiotherapy for Patients With Inoperable Soft Tissue Sarcoma.NCT07173972 · Phase 2 · Oslo University Hospital · starts Jan 26, 2026
- Hypofractionated, 3-week, Preoperative Proton or X-ray Radiotherapy for Patients With Localized Soft Tissue SarcomaNCT07169344 · Phase 2 · Oslo University Hospital · starts Jan 26, 2026
- Sequential Infusion of CD146-Targeted and HER2-Targeted CAR T Cells in Patients With Advanced SarcomasNCT07066982 · Phase 1 / Phase 2 · Essen Biotech · starts May 29, 2025
- ACTengine® IMA203 Combined With mRNA-4203NCT06946225 · Phase 1 · Immatics US, Inc. · starts Jul 25, 2025
Approved 1
- Afamitresgene autoleucelMelanoma-associated antigen 4 binding agent
Phase 3 4
- DacarbazineDNA inhibitor
- DoxorubicinDNA topoisomerase II alpha inhibitor
- IfosfamideDNA inhibitor
- CatequentinibVascular endothelial growth factor receptor 2 inhibitor
Phase 2 3
- BevacizumabVascular endothelial growth factor A inhibitor
- IpilimumabCytotoxic T-lymphocyte protein 4 inhibitor
- Lorvotuzumab mertansineNeural cell adhesion molecule 1 binding agent
Phase 1 or earlier 12 of 15
- CyclophosphamideDNA inhibitor
- DocetaxelTubulin inhibitor
- EverolimusFK506-binding protein 1A inhibitor
- AldesleukinInterleukin-2 receptor agonist
- Prasterone
- ImatinibTyrosine-protein kinase ABL inhibitor
- DecitabineDNA (cytosine-5)-methyltransferase 3A inhibitor
- FilgrastimGranulocyte colony stimulating factor receptor agonist
- GemcitabineRibonucleoside-diphosphate reductase RR1 inhibitor
- RamucirumabVascular endothelial growth factor receptor 2 inhibitor
- PembrolizumabProgrammed cell death protein 1 inhibitor
- NivolumabProgrammed cell death protein 1 inhibitor
How its trials ended
90 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 27 whose ending is known, 19% met their primary endpoint, 0% missed it and 81% stopped early.
- Completed, result not reported3033%
- Ongoing2730%
- Stopped: other or unclear910%
- Stopped: sponsor or business decision89%
- Status unknown67%
- Met its primary endpoint56%
- Stopped: enrollment or feasibility33%
- Stopped: lack of efficacy22%
| Jul 30, 2019 | A phase 2 single arm open-label clinical trial of ADP-A2M4 spear t cells in subjects with advanced synovial sarcoma or myxoid/round cell liposarcoma (spearhead…ADP-A2M4 | Uswm CT, LLC | Ongoing |
| Jul 21, 2016 | A pilot study of genetically engineered NY-ESO-1 specific (C259) t cells in HLA-A2+ patients with synovial sarcomaNY-ESO-1C259T/ Cyclophosphamide/ Fludarabine | Adaptimmune Therapeutics | Closed |
| Jun 30, 2016 | A phase II, multicenter study of the EZH2 inhibitor tazemetostat in adult subjects with INI1-negative tumors or relapsed/refractory synovial sarcomaTazemetostat (EPZ-6438) | Ipsen | Closed |
| Jun 17, 2026 | TecelraTreatment of adults and pediatric patients 12 years of age and older with unresectable or metastatic synovial sarcoma who have received… | Uswm CT, LLC | Approved |
| Aug 1, 2024 | TecelraTreatment of adults with unresectable or metastatic synovial sarcoma who have received prior chemotherapy, are HLA-A*02:01P, -A*02:02P,… | Uswm CT, LLC | Approved |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA